Br J Cancer: A summary analysis of clinical studies of FOLFOXIRI and Beval single anti-treatment metastatic colorectal cancer.

FOLFOXIRI (5-fluorouracil, L-folate, oxaliplatin and iriticon)/bevizumab,bev has been shown to be an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC).
, however, pre-exposure to three types of cytotoxicity raises concerns about the effectiveness of treatment after the disease develops.
the study, which provided a summary analysis of the therapeutic effects of FOLFOXIRI/bev in patients participating in two random phase 3 clinical trials (TRIBE and TRIBE2), compared the effects of FOLFOXIRI/bev and doublets (FOLFOX (5-fluorouracil, L-floric acid and oxaliplatin) or FOLFIRI (5-fluorouracil, L-leafic acid, and irithion) /bev.
and assessed the rate of remission, progression-free lifetime (second PFS) and total lifetime (second OS) during treatment.
-line RECIST (Solid Tumor Efficacy Evaluation Standard) response and OIFI (no Osaliplatin and Irithicon intervals) are potential predictive indicators for reintroduction of FOLFOXIRI±bev.
triBE and TRIBE2 summary analysis flowchart shows that patients who received FOLFOXIRI±±bev had a longer second PFS (4.4 months, 3.9 months, and 6.1 months), and appears to be limited to patients who have received remission in first-line treatment (4.2 months and 4.7 months for 6.9 months), and OIFI ≥4 months for patients (6.5 months, 4.6 months and 7.2 months, respectively).
second PFS and phase II OS results after first-line FOLFOXIRI/bev therapy, first-line FOLFOXIRI/bev did not affect the efficacy of second-line therapy.
first-line reaction and longer OIFI were associated with improved response, second PFS and reintroduity of FOLFOXIRI±bev treatment strategies, but did not affect the second OS phase.
.